— Know what they know.
Not Investment Advice
Also trades as: INXB (NASDAQ) · $vol 8M

INBX NASDAQ

Inhibrx Biosciences Inc.
1W: -1.9% 1M: -13.5% 3M: -36.1% YTD: +9.9% 1Y: +257.4%
$79.68
-2.77 (-3.36%)
 
Weekly Expected Move ±8.1%
$68 $75 $82 $88 $95
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 34 · $1.2B mcap · 11M float · 3.70% daily turnover · Short 70% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.2B
52W Range20.55-155.29
Volume185,773
Avg Volume401,630
Beta3.43
Dividend$0.85
Analyst Ratings
3 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOMark Lappe
Employees109
SectorHealthcare
IndustryBiotechnology
IPO Date2024-05-29
11025 North Torrey Pines Road
La Jolla, CA 92037
US
858-795-4220
About Inhibrx Biosciences Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Recent Insider Trades

NameTypeSharesPriceDate
Vuori Kristiina MD A-Award 15,000 $95.22 2026-06-03
Kayyem Jon Faiz A-Award 15,000 $95.22 2026-06-03
FORSYTH DOUGLAS A-Award 15,000 $95.22 2026-06-03
MANHARD KIMBERLY A-Award 15,000 $95.22 2026-06-03
Matly David A-Award 50,000 $129.06 2026-04-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms